Liver Damage Clinical Trial
Official title:
Hypothermic Machine Preservation of Extended Criteria Liver Allografts for Transplantation
This is a study comparing a technique of continuous circulation to the liver as a means of preventing liver damage during transportation to the transplant hospital. This new technique of Machine Perfusion (MP) will be compared to the standard technique where the liver is maintained in a bag of solution on ice without circulation. The investigators will evaluate and compare the outcomes of the transplants with the new technique to the standard technique. There will be 24 MP patient's in the study. The investigators have previously used this technique with success in 20 human liver transplant patients. The investigators think there will be a benefit in terms of less damage to and better function of the donor liver which will result in faster recovery for the patients. This protective effect may allow us to successfully transplant more patients and prevent people from dying while waiting for a liver transplant.
It is our hypothesis that liver machine perfusion will increase the safe utilization of the
existing supply of extended criteria donor (ECD) livers by (1) increasing the quality and
duration of preservation thereby reducing the clinical effects reperfusion injury (2)
improving early outcomes in patients receiving ECD liver allografts (3) developing reliable
markers for pretransplant assessment of the potential graft (4) giving surgeons more
confidence when transplanting ECD livers and (5) allowing an avenue for ex vivo manipulation
of the liver to protect or restore a transiently injured liver.
The proposed study is a matched cohort design. Potential subjects will be recruited from the
Center for Liver Disease and Transplantation (CLDT) active Liver Transplant Waiting List. The
Principal Investigator as well as the CoInvestigators, are all actively involved in the pre
transplant evaluation process. Patients who are on the Waiting List and have provided written
consent to receive an ECD graft will be recruited for this trial. Subjects will be matched
with 24 historical control patients who received similar cold stored ECD grafts. Subjects
will be matched on known covariates including donor age, donation after cardiac death,
steatosis, both warm and cold ischemia times, recipient age, Model End-Stage Liver Disease
(MELD) score and disease etiology.
Subjects will be noncritically ill, not in an intensive care unit, and have a MELD < 35 in
order to minimize the variability in outcome in the sickest patients. All subjects must
provide written informed consent and meet the inclusion and exclusion criteria.
Subjects will be followed for one year post transplantation, in conjunction with their
routine liver transplant followup appointments. Retention of subjects for this trial will not
be a challenge, in that the followup visit time points (postoperative days 1 through the
discharge date, 7, 14, 30, 90, 180 and 365) are all consistent with our standard of care.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02329314 -
The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study)
|
N/A | |
Completed |
NCT03795844 -
COMPARISON OF LIVER RETRACTOR FOR INTRATOPERATIVE LIVER DAMAGE
|
N/A | |
Recruiting |
NCT02769754 -
Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection
|
Phase 3 |